Triple
T20061746
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | BEACOPP regimen |
E499491
|
entity |
| Predicate | componentDrug |
P82705
|
FINISHED |
| Object | bleomycin |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: bleomycin | Statement: [BEACOPP regimen, componentDrug, bleomycin]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: bleomycin Context triple: [BEACOPP regimen, componentDrug, bleomycin]
-
A.
bleomycin
chosen
Bleomycin is an antitumor antibiotic chemotherapy drug commonly used to treat cancers such as Hodgkin lymphoma and testicular cancer.
-
B.
adriamycin
Adriamycin is the brand name for doxorubicin, an anthracycline chemotherapy drug widely used to treat various cancers including lymphomas, leukemias, and solid tumors.
-
C.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
D.
Bicutan
Bicutan is a district in Taguig, Metro Manila, Philippines, known for its residential areas, government offices, and commercial developments.
-
E.
mitoxantrone
Mitoxantrone is an anthracenedione chemotherapeutic agent used primarily to treat certain cancers and multiple sclerosis by intercalating DNA and inhibiting topoisomerase II.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: componentDrug Context triple: [BEACOPP regimen, componentDrug, bleomycin]
-
A.
featuresDrug
chosen
Indicates that something (such as a product, treatment, or context) includes, involves, or prominently uses a particular drug.
-
B.
drugProduced
Indicates that a particular drug is manufactured or generated by a specified producer or source.
-
C.
coDeveloperDrug
Indicates a relationship where two or more entities jointly participate in the development of a drug.
-
D.
relatedDrug
Indicates that one drug has a specified relationship or association with another drug, such as interaction, similarity, or therapeutic linkage.
-
E.
isProdrugOf
Indicates that one substance is a precursor form that is metabolized in the body to produce the active form of another substance.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69da6276bcf48190aabbf279192a5fb4 |
completed | April 11, 2026, 3:02 p.m. |
| NER | Named-entity recognition | batch_69e6637601dc8190a07fc20844093cb7 |
completed | April 20, 2026, 5:33 p.m. |
| PD | Predicate disambiguation | batch_69e54cee7a5c819084ae4ff26419833f |
completed | April 19, 2026, 9:45 p.m. |
Created at: April 11, 2026, 3:38 p.m.